US FDA approves GE HealthCare’s diagnostic drug for the treatment of heart disease
The US Food and Drug Administration has approved a GE HealthCare diagnostic drug for use in the detection of coronary heart disease. Flyrcado, a radioactive diagnostic drug for positron emission tomography (PET) and myocardial perfusion imaging (MPI), will go on sale in some US markets in early 2025, after which it will be expanded.
POPULAR POSTS
At least 22 people died as Storm John dissipated over Mexico
October 1, 2024
Helene kills at least 90 people
October 1, 2024
LIVE STREAM